G-CSF and Erythropoietin Combination Therapy for Infarct Repair: Two Plus Two Equals Two? Editorial to: 'Cytokine Combination Theray with Erythropoietin and Granulocyte Colony Stimulating Factor in a Porcine Model of Acute Myocardial Infarction' by F.S. Angeli et al.

摘要

In the first study of cytokine-induced bone marrow cell (BMC) mobilization and infarct repair, therapy with a combination of granulocyte-colony stimulating factor (G-CSF) and stem cell factor (SCF) improved survival, reduced infarct size, and improved left ventricular (LV) function and remodeling in mice after coronary ligation [1]. Since the publication of this seminal report, a number of cytokines/ growth factors have been utilized for cardiac repair with diverse dosage regimens and experimental conditions with variable results [2]. The studies of G-CSF therapy in clinical trials have also yielded divergent outcomes, and the results of recent meta-analyses suggest that G-CSF alone may not produce significant clinical benefits in unselected patients with acute myocardial infarction (MI) [3, 4]. As a result, the true utility of cytokine therapy for infarct repair remains largely unclear at this time, and further investigation is certainly warranted.